The occurrence of macular edema as an adverse effect of fingolimod is well documented. Treatment modalities used to manage fingolimod-associated macular edema (FAME) have included nonsteroidal anti-inflammatory agents and sub-tenon injection. We describe two cases where intravitreal injection is used to successfully treat FAME in patients who were previously unsuccessfully treated with topical nonsteroidal anti-inflammatories.
MinukABelliveauMJAlmeidaDR. Fingolimod-associated macular edema: Resolution by sub-tenon injection of triamcinolone with continued fingolimod use. JAMA2013; 131(6): 802–804.
7.
CugatiSLeeAWLakeS. Fingolimod and macular edema – pathophysiology, diagnosis and management. Curr Opin Neurol2013; (In Press).
8.
NolanRGelfandJMGreenAJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology2013; 80(2): 139–144.
9.
DinkinMPaulF. Higher macular volume in patients with MS receiving fingolimod: Positive outcome or side effect?Neurology2013; 80(2): 128–129.
10.
GelfandJMNolanRSchwartzDM. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain2012; 135(Pt 6): 1786–1793.
11.
AfsharARFernandesJKPatelRD. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA2013; 131(1): 103–107.
12.
SampatKMGargS. Complications of intravitreal injection. Cur Opin Opthalmol2010; 21(3): 178–183.
